Andrew McCreath Cardio Pharma Corp COM-T DON'T BUY Apr 20, 2004

Had some interesting trial data. Shares have moved up quite nicely, but now priced with good news built-in. Fully valued.

Andrew McCreath

Unlock Rating

$6.960

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

Has something that is very competitive in arrhythmia. A good one to take a look at.

BUY

Have some excellent drugs. Data is coming out which they hope will be very good in the next 3/6 months.

TOP PICK

There were concerns on FDA approval, but he feels these are not major and the drug is good. Expect it will be taken over.

PAST TOP PICK

(A Top Pick Nov 20/06. Down 27%.) Has a nice little product and they are going through their trials and there is the talk of being a takeout. However, the market just doesn't care. Sold his holdings.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Andrew McCreath Cardio Pharma Corp COM-T DON'T BUY Apr 20, 2004

You might be interested:

Cardio Pharma Corp(COM-T)

Cardio Pharma Corp(COM-T)

Cardio Pharma Corp(COM-T)

Cardio Pharma Corp(COM-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights